Published in J Transl Med on September 26, 2011
Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer (2012) 1.82
Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res (2013) 1.01
Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett (2015) 0.91
HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia (2014) 0.90
Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy. Int J Mol Sci (2015) 0.88
Effects of ellagic Acid on angiogenic factors in prostate cancer cells. Cancers (Basel) (2013) 0.85
HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer (2013) 0.85
Interleukin-7 and interleukin-15 for cancer. J Cancer (2014) 0.78
The Prostate Cancer Patient Had Higher C-Reactive Protein Than BPH Patient. Korean J Urol (2013) 0.77
Glycosylation status of serum immunoglobulin G in patients with prostate diseases. Cancer Med (2016) 0.76
Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon. Cancer Immunol Immunother (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8.63
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 8.14
An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods (2001) 6.68
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol (2006) 6.00
Cytokine control of memory T-cell development and survival. Nat Rev Immunol (2003) 5.99
IL-21 is required to control chronic viral infection. Science (2009) 4.80
A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55
Interleukin 15: biology and relevance to human disease. Blood (2001) 4.47
IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 3.90
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol (2005) 3.82
Interleukin-7: from bench to clinic. Blood (2002) 3.01
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 2.85
Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest (2005) 2.48
PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest (2009) 2.26
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A (2003) 2.20
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage (2001) 1.63
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One (2009) 1.57
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol (2004) 1.56
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res (2010) 1.44
Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate (2005) 1.41
Characterization of the role of IL-6 in the progression of prostate cancer. Prostate (1999) 1.33
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol (2007) 1.29
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer (2004) 1.26
Immune response against dying tumor cells. Adv Immunol (2004) 1.26
C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control (2009) 1.13
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.11
Cytokine disbalance in common human cancers. Biochim Biophys Acta (2010) 1.10
Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One (2008) 1.10
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J (2010) 1.03
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol (2010) 1.02
Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun (1997) 1.02
Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate (2008) 1.01
Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother (2005) 1.00
Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol (1997) 1.00
Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate (2001) 0.99
The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res (2009) 0.97
Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res (1984) 0.95
The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol (1998) 0.93
Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res (2003) 0.91
Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine (2007) 0.89
Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo. Br J Surg (2005) 0.89
Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol (1994) 0.87
High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer (2008) 0.86
Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother (2009) 0.84
Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sci Am (2006) 0.83
Evidence for de novo synthesis of cytokines and chemokines in platelet concentrates. Vox Sang (2002) 0.78
Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy. Int J Cancer (2005) 0.77
Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma. Int J Gynaecol Obstet (2004) 0.77
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med (2012) 2.64
The role of bioreactors in tissue engineering. Trends Biotechnol (2004) 2.56
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol (2008) 2.33
Patterns of pulmonary complications associated with sirolimus. Respiration (2005) 2.20
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol (2010) 2.07
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Plasticity of clonal populations of dedifferentiated adult human articular chondrocytes. Arthritis Rheum (2003) 1.90
Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. Tissue Eng (2006) 1.86
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Age related changes in human articular chondrocyte yield, proliferation and post-expansion chondrogenic capacity. Osteoarthritis Cartilage (2004) 1.84
Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res (2003) 1.83
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol (2002) 1.82
Plasma vaporisation of the prostate: initial clinical results. Eur Urol (2009) 1.80
A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol (2009) 1.78
Real-time quantitative RT-PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro. J Cell Biochem (2002) 1.66
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer (2011) 1.62
A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer (2002) 1.60
Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol (2009) 1.60
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A (2011) 1.59
Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res (2002) 1.58
Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocr Relat Cancer (2013) 1.57
Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol (2004) 1.56
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol (2012) 1.54
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res (2003) 1.54
Intermediate-term results of retroperitoneoscopy-assisted cryotherapy for small renal tumours using multiple ultrathin cryoprobes. Eur Urol (2006) 1.53
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int (2013) 1.53
High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51
Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50
Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol (2005) 1.49
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
Seven hours to adequate antimicrobial therapy in urosepsis using isothermal microcalorimetry. J Clin Microbiol (2013) 1.45
The effect of increased maximum power output on perioperative and early postoperative outcome in photoselective vaporization of the prostate. Lasers Surg Med (2012) 1.41
Comparison of CT angiography with MR angiography in the preoperative assessment of living kidney donors. Transplantation (2008) 1.39
Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols. Urology (2013) 1.39
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int (2008) 1.37
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
A molecular signature predictive of indolent prostate cancer. Sci Transl Med (2013) 1.32
Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells (2005) 1.32
Tissue-engineered composites for the repair of large osteochondral defects. Arthritis Rheum (2002) 1.31
Insurance status and race represent independent predictors of undergoing laparoscopic surgery for appendicitis: secondary data analysis of 145,546 patients. J Am Coll Surg (2004) 1.27
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26
Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res (2005) 1.26
In vitro and in vivo evaluation of differentially demineralized cancellous bone scaffolds combined with human bone marrow stromal cells for tissue engineering. Biomaterials (2005) 1.26
Enhanced expression of ANO1 in head and neck squamous cell carcinoma causes cell migration and correlates with poor prognosis. PLoS One (2012) 1.26
Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int (2011) 1.25
New dimensions in tumor immunology: what does 3D culture reveal? Trends Mol Med (2008) 1.22
Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol (2002) 1.22
Complications of laser prostatectomy: a review of recent data. World J Urol (2010) 1.22
Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int (2009) 1.21
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med (2006) 1.21
ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol (2011) 1.21
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res (2002) 1.21
Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer (2005) 1.20
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology (2007) 1.19
Experimental comparison of high power (80 W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol (2004) 1.18
Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol (2003) 1.17
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 1.16
Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer (2006) 1.15
Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res (2007) 1.15
Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res (2012) 1.14
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother (2002) 1.14
NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer (2005) 1.13
Photoselective vaporization of the prostate: the basel experience after 108 procedures. Eur Urol (2005) 1.12
Lubricin reduces cartilage--cartilage integration. Biorheology (2004) 1.12
Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol (2010) 1.11
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol (2006) 1.11
High hospital volume is associated with better outcomes for breast cancer surgery: analysis of 233,247 patients. World J Surg (2005) 1.11
Cell yield, proliferation, and postexpansion differentiation capacity of human ear, nasal, and rib chondrocytes. Tissue Eng (2004) 1.09
Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol (2013) 1.09
Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer (2007) 1.08
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother (2011) 1.08
Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia (2002) 1.07
Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol (2002) 1.07
Expression of NKX3.1 in normal and malignant tissues. Prostate (2003) 1.07
Effects of scaffold composition and architecture on human nasal chondrocyte redifferentiation and cartilaginous matrix deposition. Biomaterials (2005) 1.07